6-phosphofructokinase 1 (PFK-1)

6-phosphofructokinase 1 (PFK-1) is the critical, rate-limiting enzyme in the glycolytic pathway, responsible for the ATP-dependent conversion of fructose-6-phosphate to fructose-1,6-bisphosphate (StatPearls: Glycolysis, 2023). It exists as a tetrameric complex composed of three tissue-specific subunits: muscle (PFKM), liver (PFKL), and platelet (PFKP), allowing for fine-tuned metabolic control across different organs (UniProt: P08237, P17858, Q01813). PFK-1 acts as a metabolic sensor, highly regulated by allosteric effectors such as ATP, AMP, and fructose-2,6-bisphosphate to maintain cellular energy homeostasis (PubMed: 26453303). In oncology, PFK-1 is frequently upregulated to support the Warburg effect, providing cancer cells with the metabolic intermediates necessary for rapid proliferation (PubMed: 30206110). Conversely, genetic deficiency in the PFKM subunit leads to Tarui disease, a metabolic disorder characterized by exercise intolerance and myogenic symptoms (NIH: GARD). While direct PFK-1 inhibitors like clotrimazole have been studied in research settings to disrupt tumor metabolism, the enzyme's fundamental role in systemic energy production presents a significant challenge for achieving therapeutic selectivity without adverse metabolic side effects (PubChem).

Other names

Phosphofructokinase 1PFK16-phosphofructokinase type APhosphofructo-1-kinaseATP-dependent phosphofructokinase6-phosphofructokinase, muscle type (PFKM)6-phosphofructokinase, liver type (PFKL)6-phosphofructokinase, platelet type (PFKP)

Allosteric inhibition of the enzyme to reduce glycolytic flux; Allosteric activation to bypass metabolic blocks; Direct enzymatic inhibition of the fructose-6-phosphate binding site.